ADA-friendly PDF: Pembrolizumab in Early-Stage TNBC

Treatment Guidelines: Pembrolizumab for Early-Stage Triple-Negative Breast Cancer

The Dana-Farber Brigham Cancer Center Breast Oncology Center (BOC) held multidisciplinary meetings on August 4, September 3, and October 8, 2021 to discuss recommendations for the use of pembrolizumab in patients with early-stage TNBC.